I hereby certify that this correspondence is being deposited with the United States Postal Service first class mail in an envelope addressed to:

Commissioner for Patents, P.O. Box 1450

Alexandria, VA 22313 on

ice is APR 2 3 2004 S

INFORMATION DISCLOSURE STATEMENT Examining Group 1642 Patent Application Docket No. GJE-48D1 Serial No. 10/618,570

Doran R. Pace, Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit

1642

Applicants

Seppo Yla-Herttuala, Markku Kulomaa, Pauliina Lehtolainen, Varpu

Marjomaki, Kari Airenne

Serial No.

10/618,570

Filed

July 11, 2003

For

Biotin-Binding Receptor Molecules

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§1.97 AND 1.98

Sir:

In accordance with 37 CFR §1.97 and §1.98, Applicants would like to bring to the attention of the Examiner, the references cited in the following patent application:

U.S. Serial No. 09/622,804, which entered the U.S. national stage on August 22, 2000, from international application No. PCT/GB99/00546, filed February 23, 1999.

The subject application, Serial No. 10/618,570, claims the benefit under 35 USC §120 of the filing date of patent application Serial No. 09/622,804. Applicants respectfully request that the references cited in the Information Disclosure Statement submitted in the 09/622,804 application, as well as any references cited by the Patent Office during the prosecution thereof, be made of record in the 10/618,570 application. As copies of the references made of record in the 09/622,804 application,

Docket No. GJE-48D1 Serial No. 10/618,570

2

and cited on the attached form PTO/SB/08, can be found in the 09/622,804 casefile, copies of those references are not provided herewith.

It is respectfully requested that the references cited on the attached form PTO/SB/08 be considered in the examination of the subject application and that their consideration be made of record.

Applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statements.

Respectfully submitted,

Doran R. Pace

Patent Attorney

Registration No. 38,261

Phone No.:

352-375-8100

Fax No.:

352-372-5800

Address:

2421 N.W. 41st Street, Suite A-1

Gainesville, FL 32606-6669

DRP/sl

Attachment: Form PTO/SB/08

OTP E 1000 APR 2 3 2004

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwark Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

+

Complete if Known Substitute for form 1449A/PTO **Application Number** 10/618,570 INFORMATION DISCLOSURE Filing Date July 11, 2003 STATEMENT BY APPLICANT First Named Inventor Seppo Yla-Herttuala (use as many sheets as necessary) **Art Unit** 1642 **Examiner Name** Sheet of **Attorney Docket Number** 2 GJE-48D1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. 1	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
7	U1	US- 5,457,035	10-10-1995	Baum <i>et al.</i>	All
	U2	US- 5,510,466	04-23-1996	Krieger <i>et al.</i>	All
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*		Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т
	Cite No. ¹	Country Code 3 - Number 4 - Kind Code 5 (if known)				T⁴
				The Trustees of		
	F1	WO 87/05026	08-27-1987	Columbia University in the city of New York	All	[
	F2	WO 96/40761 A1	12-19-1996	Rosebrough	All	
	F3	WO 97/19957	06-05-1997	New York University	All	
	F4	EPO 03/59347	03-21-1990	NEORX Corporation	All	
	F5			· · · · ·		
	F6					
	F7					

Examiner	Date
0:	
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

OIPE C 23 2004 P

Sheet

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Page work Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

2

Complete if Known			
Application Number	10/618,570		
Filing Date	July 11, 2003		
First Named Inventor	Seppo Yla-Herttuala		
Group Art Unit	1642		
Examiner Name			
Attorney Docket Number	GJF-48D1		

	NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	R1	Rihova, B., "Targeting of Drugs to Cell Surface Receptors," Critical Reviews in Biotechnology 1997, Vol. 17, No. 2, pp.149-169.			
	R2	Kulomaa, M. S. et al., "A Production of Recombinant Avidin and Avidin-Fusion Proteins in Bacterial and Insect Cells", FASEB Journal 1995, Vol. 9, No. 6, p. A1395, XP-002112828, abstract only.			
	R3	Marjomaki, V. et al., "Efficient Transport of Avidin Fusion Proteins Into Late and Early Endosomes", <i>Molecular Biology of the Cell</i> 1996, Vol. 7 (Supp. S), p. 2631, XP-002112829, abstract only.			
	R4				
	R5				
	R6				
	R7				
	R8				
	R9				
	R10				
<u></u>	R11				
· · ·	R12				
	R13				

Examiner	Date	
Signature	Considered	<u> </u>

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.